Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2009 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.Contact:NeurologixMarc Panoff, 201-592-6451Chief Financial Officermarcpanoff@neurologix.net-- Financial tables to follow--NEUROLOGIX, INC.
    (A Development Stage Company)
    BALANCE SHEETS
    (Amounts in thousands, except share and per share amounts)September 30,
    2010December 31,
    2009(Unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $3,004

    $9,637Prepaid expenses and other current assets

    158

    395Total current assets

    3,162

    10,032Equ
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Spherix Reports Second Quarter Earnings
    5. Tapestry Reports Second Quarter 2007 Results
    6. Callisto Reports on Second-Quarter 2007 Milestones
    7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    11. Biopure Reports on Meeting with the FDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
    (Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
    (Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
    Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
    ... Mich. , May 4 Stryker‘s Communications ... have signed an agreement to integrate both companies’ technologies ... this collaboration, operating rooms containing the da ... System will provide surgeons and OR staff more flexibility ...
    ... Two Roche employees were recognized for their significant ... TWIN Awards Dinner held April 29 , 2010.  Honored were ... M. Fieldstad , Pharm.D., global head, Safety Compliance, Pharmaceutical Development Safety and ... "These women ...
    Cached Medicine Technology:Stryker Enters Strategic Marketing Agreement With Intuitive Surgical 2Stryker Enters Strategic Marketing Agreement With Intuitive Surgical 3Roche Women Honored as 2010 TWIN Awardees 2Roche Women Honored as 2010 TWIN Awardees 3Roche Women Honored as 2010 TWIN Awardees 4Roche Women Honored as 2010 TWIN Awardees 5
    (Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
    (Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
    (Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
    (Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
    (Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
    Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
    ... Stigma Associated with Mental ... Health Concerns, ... currently being recognized on TIME.com as,one of the best Web Sites ... TIME.com cites Psych Central,s simple quizzes, "Ask the,Therapist" area, and prescription ...
    ... a dainty, quill-like sea creature called a lancelet provides the ... million years through a four-fold duplication of the genes of ... argued in 1970 that gene duplication was the most important ... was the basis for original estimates that the human genome ...
    ... natural Hyaluronic Acid ... LEXINGTON, Ky., June 18 Renowned surgeon and co-founder,of ... Joseph E. Kutz has,specialized in hand and reconstructive microsurgery ... number of patients, from youths to seniors,suffering from arthritis ...
    ... of Data into Valid,Accurate and Consumer-Friendly Information, ... new five-star rating system for nursing facilities announced ... (CMS), the Alliance for,Quality Nursing Home Care noted ... and timely quality information and its desire,to work ...
    ... Inc.,(Nasdaq: HOLX ) today announced that Glenn Muir, ... Annual Healthcare Conference being,held June 24 - 26, 2008, ... Interested parties are invited to listen to a ... 25, 2008, at 12:30 PM.,Eastern Time on the investor ...
    ... YORK (June 18, 2008) -- Could injecting a gene ... disabling and life-threatening condition? Physician-scientists are setting out to ... gene therapy to treat severe heart failure. , ... in the New York City area where the therapy ...
    Cached Medicine News:Health News:Psych Central Selected by TIME Magazine as Top 50 Web Site in 2008 for Its Top Mental Health Content and Social Media Platform 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 3Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 4Health News:World Renowned Hand Surgeon Helps Patients 'Conquer' Joint Discomfort Naturally 2Health News:Alliance Expresses Support for Concept Underlying New CMS 'Five-Star' Rating System for Nursing Facilities 2Health News:Alliance Expresses Support for Concept Underlying New CMS 'Five-Star' Rating System for Nursing Facilities 3Health News:Hologic to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2
    ... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
    ... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
    For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
    For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
    Medicine Products: